Patent ID: 8802157

Claim:
A method for treating a subject diagnosed with epilepsy, psychiatric disorders, neuropathic pain or movement disorder, comprising administering to the subject an extended release oral dosage form comprising an osmotic device comprising a core comprising gabapentin and a semipermeable membrane surrounding the core, wherein the semipermeable membrane comprises a plasticizer, is permeable to a fluid in an environment of use and is substantially impermeable to unsolubilized gabapentin, wherein the oral dosage form as formulated is of sufficient size to promote retention in the stomach of the subject in the fed mode for a period of at least 5 hours, and wherein the gabapentin is released into the upper gastrointestinal tract over a period of about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration (C max ) compared to an equal dose of gabapentin provided by an immediate release dosage form.